Roche takes a shot in obesity

Roche has fired a warning shot across the bow of Eli Lilly and Novo Nordisk, paying $4.7 billion for a US biotech with Phase 2 assets targeting obesity.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here